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Abstract 
Objectives: There are few data on clinical profiles of ANCA-associated vasculitis (AAV) in 
different ethnic populations. This study examined differences in the ANCA type and clinical 
features of AAV between populations using the Diagnostic and Classification Criteria in 
Vasculitis Study (DCVAS) dataset. 
 
Methods: DCVAS is an international, multi-center, observational study recruiting in 133 sites. 
Eight ethnic categories were analysed: Northern European, Caucasian American, Southern 
European, Middle Eastern/Turkish, Chinese, Japanese, Indian subcontinent, and other. ANCA 
type was categorized as myeloperoxidase (MPO), proteinase 3 (PR3), and ANCA-negative. 
Organ system involvement was recorded using a standard dataset. Differences were analysed 
by chi-squared tests using a Bonferroni correction, and logistic regression (adjusting for age 
& sex). Northern European was the reference population. 
 
Results:  Data from 1,217 patients with AAV were available, and the 967 (79.5%) patients 
recruited by Rheumatology were analysed to reduce confounding by recruitment specialty. 
There were differences in ANCA type between ethnic categories (p<0.001): MPO-ANCA was 
more common than PR3-ANCA in Japanese, Chinese, and Southern Europeans; PR3-ANCA was 
more common in the other groups. Compared to Northern Europeans, Japanese had a nearly 
60-fold increased chance of having MPO-ANCA (vs. PR3-ANCA) (OR 59.2, 95%CI 8.0-440.7, 
p<0.001), and Chinese had a nearly 7-times increased chance (OR 6.8, 95%CI 2.6-17.8, 
p<0.001). 
 
Ophthalmologic and otorhinolaryngologic involvement were less common in Japanese and 
Chinese populations than Northern Europeans; otherwise, there were few differences in 
organ involvement between ethnic groups. 
 
Conclusion: This study confirms the previously observed differential occurrence of MPO-AAV 
and PR3-AAV between different ethnic groups. 
 
Key words: ANCA-vasculitis, epidemiology, PR3-ANCA, MPO-ANCA 
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Background 
Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a group of conditions 
characterised by necrotising vasculitis and the presence of ANCA in serum. The three types of AAV, 
granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), and 
microscopic polyangiitis (MPA), are distinguished by their clinical features and ANCA type. 
Geoepidemiological data from Europe suggests that GPA is more common than MPA in Northern 
Europe, whilst the reverse is reported in Southern Europe.(1,2) A comparative study between the 
United Kingdom (UK) and Japan observed that the overall incidence of AAV was similar, but that MPA 
and myeloperoxidase (MPO) positive-AAV (MPO-AAV) was the predominant type in Japan (>80%) and 
proteinase 3 (PR3) positive-AAV (PR3-AAV) (>60%) the predominant type in the UK.(3) Case series 
from China suggest that MPA is more common than GPA.(4) In a multi-ethnic series from Chapel Hill 
in the USA, GPA was less common in African Americans.(5) Anecdotal evidence from European experts 
in vasculitis suggests that MPO-ANCA is more common in Southern Europe, whilst data from China 
suggests that MPO-ANCA is more common than PR3-ANCA.(4) 
The UK-Japan comparative study suggested that respiratory and otorhinolaryngologic involvement 
was less common in the Japanese patients with AAV than in the UK; for the GPA subset respiratory 
and renal involvement was less common in Japan.(3) A recent study of the clinical features of GPA 
patients in France noted that black patients (i.e. sub-Saharans and Afro-Caribbeans had more severe 
granulomatous manifestations and shorter time to relapse. (6) 
There are few comparative data on the clinical profiles of patients with AAV in other populations, 
particularly using clinical data collected globally with a standardised method. 
The Diagnostic and Classification of Vasculitis (DCVAS) study is an international observational study 
with the aim of developing new classification criteria for AAV.(7) The dataset contains rich data on the 
clinical features of patients from many different countries and ethnic backgrounds. The goal of the 
present study was to investigate the hypothesis that there are differences in the clinical presentations 
of patients with AAV of different ethnicity.  
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Methods 
The methodology for DCVAS has been described previously.(7) Patients used in this analysis were 
recruited into DCVAS between September 2014 and March 2016. We included patients with a 
diagnosis of ANCA-associated vasculitis (AAV) provided by their Physician-investigators. As there are 
no published classification criteria for ANCA-associated vasculitis, the DCVAS team have validated the 
diagnosis of these patients using external expert review and this analysis demonstrated a high degree 
of agreement with the original diagnosis of AAV (DCVAS unpublished data). Data on ethnicity, age, 
sex, ANCA status (ANCA-PR3, ANCA-MPO positive, ANCA negative), specialty of referring clinic, and 
clinical features were extracted. Organ involvement at presentation was assessed using a standard 
form, documenting the presence or absence of disease in eleven organ systems 
(general/constitutional, musculoskeletal, skin, ophthalmic, otorhinolaryngologic, respiratory, cardiac, 
gastrointestinal, genitourinary, renal and neurological).  
Ethnicity was recorded by the referring physician in one of the following 19 groups: African North, 
African Sub-Saharan, African-American, Black Caribbean, Chinese Han, Chinese other, European 
North, European South, Indian subcontinent (Indian, Pakistani/Bangladeshi), Japanese, Korean, Latin 
American -Native, Latin American - Mestizo, Middle Eastern, Pacific Islander, Turkish, White 
Caucasian American, and other. The study subdivided patients of European ethnicity into Northern 
and Southern. We based this subdivision on genetic studies of European population substructure, 
which suggest that there is a North – South genetic variation. Based on this we categorized patients 
from Spain, Italy, Greece and the Balkans as Southern European, and patients from the United 
Kingdom, Ireland, the Nordic countries, the Benelux countries (Belgium, Netherlands, and 
Luxembourg), Estonia, Latvia and Lithuania, Slovakia, France, Germany, Austria, and Poland as 
Northern Europeans (8). Ethnicity was categorized for analysis into 8 groups: Northern European, 
Caucasian American, Southern European, Middle Eastern/Turkish, Chinese, Japanese, Indian 
subcontinent and other. Patients with more than one ethnicity recorded were coded as other.  
Missing data were quantified, and the one missing age value was imputed from the median for the 
cohort. 
Age, sex, and recruiting specialty were identified from the literature as likely to be associated with 
both ethnicity, and our outcomes (ANCA-type and clinical features),(2,3) and these were considered 
a priori confounders. Age (continuous variable) and sex (binary variable) were adjusted for in the 
statistical analysis. However, with 6 specialties, and zero values for some specialties in some ethnic 
categories, statistical adjustment was not possible so the analysis was limited to only patients 
recruited from the largest recruiting specialty. 
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Ethical approval was obtained at all sites. Participants consented to the study and access to their 
records was granted. The procedures followed were in accordance with the ethical standards of the 
local responsible committee on human experimentation and with the Helsinki Declaration of 1975, as 
revised in 1983. 
Statistical analysis 
We tested whether there were differences in the ANCA type (MPO-ANCA, PR3-ANCA or ANCA 
negative) of patients from each ethnic category using Chi-squared tests of 8x3 contingency tables. We 
calculated the odds ratio (OR) for MPO-ANCA compared to PR3-ANCA in each ethnic category by 
logistic regression, and then adjusted this for age and sex. Correction for multiple testing was done by 
the Bonferroni method, using 8 variables and accordingly we set the significance level at p<0.0063.  
We also investigated whether there were differences in the presence of symptoms in each organ 
system between ethnic categories by Chi-squared tests of 8x2 contingency tables. Correction for 
multiple testing was done by the Bonferroni method, using 11 variables and accordingly we set the 
significance level at p<0.0045. We calculated the odds ratio (OR) for involvement of each organ system 
in each ethnic group using logistic regression with the European North ethnic category (the largest 
group) as the reference population, and then adjusted this for age and sex. We have also separately 
reported ethnic groups in which organ systems were affected +/- 2 fold as often as the reference 
(northern European) group (OR<0.5 or OR>2); so that large effects in small ethnic groups were not 
missed due to not reaching statistical significance because of their small sample size. 
Statistical analysis was carried out using STATA version 14 (Stata Corp LP, Texas)  
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Results 
We used the DCVAS dataset (as of 22 March 2016). There were 1,217 patients who had a diagnosis of 
AAV and were included in the study. The largest recruiting specialty was rheumatology, which 
recruited 967 (79.5%) patients, 212 (17.4%) patients were recruited by nephrology clinics, and a small 
number of patients were recruited from immunology, neurology, respiratory, and dermatology clinics 
(totalling 38, 3.0%). There was differential recruitment between specialties, in northern Europe only 
10% of patients were recruited from nephrology clinics whereas in Chinese patients 60% were 
recruited from nephrology clinics. (Figure 1 and online supplementary table 1). To control for this we 
chose to confine our analysis to patients recruited from rheumatology clinics. Table 1 gives the 
ethnicity breakdown, clinical diagnosis, and ANCA status of both the whole cohort and the patients 
recruited from rheumatology. The median age of the patients recruited from rheumatology was 57.5 
years (interquartile range (IQR) 45.2-67.6). This was similar to the age distribution of the whole cohort 
(median 58.3 years, IQR 45.6-68.3). 
ANCA-type 
The frequency of PR3-ANCA varied between 61.2% in Northern Europeans and 2.1% in Japanese, and 
the frequency of MPO-ANCA varied between 24.6% in Northern Europeans and 81.3% in Japanese 
(table 2 and supplementary online figure 2). Compared to Northern Europeans, Japanese had a 
nearly 60-fold increased chance of having MPO-ANCA (rather than PR3-ANCA) (OR 59.2, 95%CI 8.0-
440.7, p<0.001) and Chinese had a nearly 7-fold increased chance of having MPO-ANCA (OR 6.8, 
95%CI 2.6-17.8, p<0.001). There was also a significantly increased chance of having MPO-ANCA 
(rather than PR3-ANCA) compared to Northern Europeans in Caucasian Americans (OR 2.6, 95%CI 
1.7-4.0, p<0.001) and Middle Eastern/Turkish (OR 2.3, 95%CI 1.3-4.2, p=0.005); a similarly increased 
chance of MPO-ANCA (compared to PR3-ANCA) was found in Southern Europeans (OR 2.6, 95% CI 
1.3-5.0, p=0.006) but this finding was not statistically significant. 
The distribution of MPO- and PR3- ANCA in each ethnic group was similar in the whole sample of 
1217 patients to that seen in the 967 recruited from rheumatology clinics (supplementary online 
figures 1-2). 
The frequency of ANCA-negative AAV ranged between 14.2% in Northern Europeans and 33.3% in 
Chinese. In Caucasian Americans the frequency of ANCA-negative AAV was 25.3%, and this was 
statistically significantly higher than in Northern Europeans  (OR 2.0, 95% CI 1.3-3.2, p=0.002). In 
Chinese, the odds ration for ANCA-negative AAV compared to Northern Europeans was higher (OR 
2.7, 95% CI 1.2-5.9, p=0.014) but this was not statistically significant. 
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Clinical Profiles 
In the rheumatology group ophthalmologic, otorhinolaryngologic and renal involvement were 
significantly different among the ethnic categories (table 3). Ophthalmologic involvement was 25 
times less common in Japanese compared to Northern Europeans, and the effect remained reduced 
at 7 times less common in the MPO-ANCA subgroup, implying this difference was not driven entirely 
by the differences in predominant ANCA-types. Otorhinolaryngologic involvement was five times 
less common in Japanese, and half as common in Chinese compared to Northern Europeans. In the 
MPO-ANCA subgroup these effects reduced to 60% less common in Japanese and 40% less common 
in Chinese again suggesting an effect of ethnicity that is in addition to the influence of ANCA-type. 
Renal involvement was less common in Caucasian Americans (OR 0.6, 95% CI 0.4-0.9), and more 
common in the Middle Eastern/Turkish (OR 1.8, 95% CI 1.1-2.9) and Indian/Pakistani/Bangladeshi 
(OR 1.8, 95% CI 1.0-3.3) categories compared to Northern Europeans. 
Although overall the differences in the distribution of general/constitutional, cardiac, and 
genitourinary organ systems were not significant, some small ethnic groups showed rates of 
involvement that were more than ±2 fold that found in Northern Europeans. These included 
constitutional/general symptoms were less common in Southern Europeans (OR 0.4, 95% CI 0.2-0.8), 
cardiac involvement was less common in Middle Eastern/Turkish (OR 0.4, 95% CI 0.2-0.9) and people 
from the Indian subcontinent (OR 0.4, 95% CI 0.2-1.3), and genitourinary involvement was less 
common in Southern Europeans (OR 0.3, 95% CI 0.1-1.2) and Chinese (OR 0.2, 95% CI 0.0-1.7).  
Results for the whole sample of 1217 patients and the subgroup of 212 patients recruited by 
Nephrology clinics are shown in supplementary online table 2 for comparison. 
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Discussion 
In this study we have for the first time compared the clinical presentations and ANCA status of patients 
with AAV in a large (1217 patient) multinational cohort using a standardised assessment. This is one 
of the largest of cohorts of AAV patients assembled. 
The main findings of this analysis are that MPO-AAV is the predominant subtype of AAV in the 
Japanese group where it comprises 81.3% of AAV, and in the Chinese group where it comprises 45.4% 
of AAV, which is not the same pattern as found in Northern Europeans. This difference was the same 
in the whole cohort as in the rheumatology patients. In our analysis there were few significant 
differences in the clinical profiles of patients of different ethnicities. 
The major strength of this study is the widespread international recruitment with patients being 
recruited from 133 centres in 33 countries, together with the standardised collection of clinical data. 
This has enabled us to compare the clinical features and ANCA status across different ethnicities and 
countries. We have applied stringent criteria for significance testing with correction for multiple 
comparisons and we are thus only reporting differences with strong effects.  
The main limitation of this type of study is the potential for selection bias. The patients who are 
included may not be representative of all patients of that ethnicity, meaning either spurious 
associations may be reported, or true associations may not be found. We had also been concerned 
that differences in ANCA-types and clinical features of patients would occur between those recruited 
from different specialties, such as the differences in ANCA-types and clinical features between 
patients presenting to nephrology and rheumatology services.(9) Because each specialty did not 
recruit an equal proportion of patients from each ethnicity, we limited our main analysis to patients 
recruited only by the largest recruiting specialty (rheumatology). This reduced the impact of this bias 
while only slightly reducing the power of our study to detect differences and reducing the sample size 
from 1217 to 967. Previous studies have not addressed this issue.(3,4) 
The other main limitation is a problem inherent in the study of rare diseases. Despite recruiting >1000 
patients, there remained small numbers of patients in some subgroups, which meant that we were 
unable to perform a separate analysis for PR3-AAV and MPO-AAV, and differences in some smaller 
ethnic groups had large effect sizes (more than ±2 fold difference from the Northern European 
reference group) but were not statistically significant. Therefore, in addition to results that are 
statistically significant, we have reported results which estimate a more than ±2 fold difference from 
the Northern European reference group, as these could be clinically relevant. 
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The observed differences in MPO-AAV and PR3-AAV between Northern Europe, Southern Europe, 
Japan, and China and could represent the effect of different genetic backgrounds. HLA DPB1*0401 is 
the major HLA susceptibility allele for GPA in European populations, but shows major variation 
worldwide. (10,11) There is a fairly consistent allele frequency in Europe of around 0.36-0.47. The 
allele is much less frequent in Japan (0.050) and China (0.095-Han Cantonese), two populations in this 
study in which PR3-AAV is less common. In a small population of Han Chinese PR3-AAV was associated 
with DRB1*1202 which is relatively more common in that population than in Europe. (12) The two 
major non-HLA associated SNPs in a GWAS were SERPINA1 and PRTN3. Serpina 1 encodes alpha1 anti-
trypsin, haplotype analysis suggests that the causal variant is either the Z allele or in close linkage 
disequilibrium with it.(11) The PI*Z allele of the alpha-1 antitrypsin gene shows widespread variation 
in its geo-epidemiology (13) but its frequency does not appear to parallel that of GPA. (14) There are 
presently insufficient data on the occurrence of PRTN3 (which encodes the PR3 gene) to determine 
whether its frequency mirrors that of GPA. The genetic background of MPA is less well known. 
However, it clearly has a different HLA background, in the European GWAS HLA DPB1*0401 was not 
associated with MPA or MPO-ANCA vasculitis, but with HLA-DQ. (11) (15). In Japanese populations 
DRB1*0901 and DQB1*03:03 are associated with MPA and MPO-AAV and are among the most 
frequent HLA class II haplotypes in East Asian populations; these haplotypes are rare in in populations 
of European and African ancestry.(16) 
Conclusions 
In this global study of the clinical features of AAV, we have shown that PR3-AAV is the predominant 
type of vasculitis in Northern Europeans, Middle Eastern/Turkish and people from the Indian 
subcontinent whilst MPO-AAV is the predominant type of vasculitis in Japanese and Chinese 
populations. MPO-AAV and PR3-AAV occur with similar frequency in Caucasian Americans and 
Southern Europeans. Apart from the reduced occurrence of otorhinolaryngologic and 
ophthalmological involvement in Chinese and Japanese populations we demonstrated few differences 
in the clinical presentations of AAV in different ethnic groups. In the context of such a rare disease the 
large number of patients included in this study represents hugely successful collaboration. 
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Tables 
Table 1: Demographics, Recruiting Specialties, Diagnoses, and ANCA Types of the Cohort 
  N (%) of all 1217 
patients 
N (%) of 967 patients  
from Rheumatology 
Sex Male 594 (48.8) 487 (50.4) 
 Female 623 (51.2) 480 (49.6) 
Ethnic category European North 486 (39.9) 427 (44.2) 
 Caucasian American 186 (15.3) 185 (19.1) 
 European South 100 (8.2) 54 (5.6) 
 Middle Eastern /Turkish 92 (7.6) 91 (9.4) 
 Chinese 81 (6.7) 35 (3.6) 
 Japanese 64 (5.3) 51 (5.3) 
 Indian subcontinent 60 (4.9) 52 (5.4) 
 Other 148 (12.1) 72 (7.5) 
Recruiting Specialty Rheumatology 967 (79.5) 967 (100) 
Nephrology 212 (17.4)  
 Immunology 28 (2.3)  
 Neurology 5 (0.5)  
 Respiratory 3 (0.3)  
 Dermatology 2 (0.2)  
ANCA-type PR3 499 (41.0) 422 (43.6) 
 MPO 414 (34.0) 287 (29.7) 
 Negative 189 (15.0) 165 (17.1) 
 Other* 115 (8.5) 93 (9.6) 
*This category either had not had their ANCA tested (n=17), were both PR3-positive and MPO-positive (n=9), or 
only had ANCA found on immunofluorescence testing (n=89). 
ANCA = anti-neutrophil cytoplasmic antibody, , PR3 = proteinase 3, MPO = myeloperoxidase. 
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Table 2: Distribution of ANCA-types by ethnicity for the patients recruited in rheumatology clinics 
 PR3 MPO 
ANCA-
negative 
Crude OR 
(95% CI) 
ANCA-neg 
compared to 
MPO/PR3 
Adjusted OR 
(95% CI)† 
ANCA-neg 
compared to 
MPO/PR3 
p-value 
Crude OR  
(95% CI) 
MPO compared 
to PR3 
Adjusted OR 
(95% CI)† 
MPO compared 
to PR3 
p-value 
Northern European 237 (61.2) 95 (24.6) 55 (14.2) 1 1  1 1  
Caucasian American 64 (37.7) 63 (37.1) 43 (25.3) 2.0 (1.3-3.2) 2.0 (1.3-3.2) 0.002* 2.5 (1.6-3.7) 2.6 (1.7-4.0) <0.001* 
Southern European 20 (37.0) 22 (40.7) 12 (22.2) 1.7 (0.9-3.5) 1.8 (0.9-3.7) 0.093 2.7 (1.4-5.3) 2.6 (1.3-5.0) 0.006 
Middle Eastern / Turkish 38 (50.0) 25 (32.9) 13 (17.1) 1.2 (0.6-2.4) 1.1 (0.6-2.1) 0.794 1.6 (0.9-2.9) 2.3 (1.3-4.2) 0.005* 
Chinese 7 (21.2) 15 (45.4) 11 (33.3) 3.0 (1.4-6.6) 2.7 (1.2-5.9) 0.014 5.3 (2.1-13.5) 6.8 (2.6-17.8) <0.001* 
Japanese 1 (2.1) 39 (81.3) 8 (16.7) 1.2 (0.5-2.7) 1.6 (0.7-3.7) 0.274 97.3 (13.2-718.3) 59.2 (8.0-440.7) <0.001* 
Indian subcontinent 26 (59.1) 11 (25.0) 7 (15.9) 1.1 (0.5-2.7) 0.9 (0.4-2.2) 0.818 1.1 (0.5-2.2) 1.7 (0.8-3.8) 0.174 
Other 29 (46.8) 17 (27.4) 16 (25.8) 2.1 (1.1-4.0) 1.8 (0.9-3.4) 0.076 1.5 (0.8-2.8) 1.9 (1.0-3.8) 0.058 
Table includes 874 patients with ANCA recorded; 93 either had not had their ANCA tested (n=14), were both PR3-positive and MPO-positive (n=6), or only 
had ANCA found on immunofluorescence testing (n=73). 
† Adjusted for age and sex 
*=statistically significant using Wald’s test, at 0.0063 using a 95% significance level and the Bonferroni correction for testing 8 variables 
ANCA = anti-neutrophil cytoplasmic antibody, PR3 = proteinase 3, MPO = myeloperoxidase, OR = odds ratio, CI = confidence intervals. 
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Table 3: Involvement of organ systems by ethnicity for 967 patients with ANCA-associated vasculitis 
recruited in Rheumatology clinics 
 
 
N (%) 
affected 
p value Crude OR (95% CI) † Adjusted OR (95% CI) 
R
e
n
al
 
Northern European 115 (25.9) 0.001** 1 1 
Caucasian American 32 (17.3) 0.6 (0.4-0.9) 0.6 (0.4-0.9) 
Southern European 19 (35.2) 1.5 (0.8-2.7) 1.4 (0.8-2.6) 
Middle Eastern / Turkish 35 (38.5) 1.7 (1.1-2.7) 1.8 (1.1-2.9) 
Chinese 11 (31.4) 1.2 (0.6-2.6) 1.3 (0.6-2.8) 
Japanese 21 (41.2) 1.9 (1.0-3.5) 1.7 (0.9-3.2) 
Indian subcontinent 19 (36.5) 1.6 (0.9-2.9) 1.8 (1.0-3.3) 
Other 25 (34.7) 1.4 (0.8-2.5) 1.6 (0.9-2.7) 
C
o
n
st
it
u
ti
o
n
al
/G
e
n
e
ra
l 
Northern European 350 (82.0) 0.074 1 1 
Caucasian American 142 (76.8) 0.7 (0.5-1.1) 0.7 (0.5-1.1) 
Southern European 36 (66.7) 0.4 (0.2-0.8) 0.4 (0.2-0.8)* 
Middle Eastern / Turkish 79 (86.8) 1.4 (0.8-2.8) 1.7 (0.9-3.2) 
Chinese 27 (77.1) 0.7 (0.3-1.7) 0.8 (0.4-1.9) 
Japanese 39 (76.5) 0.7 (0.4-1.4) 0.6 (0.3-1.1) 
Indian subcontinent 45 (86.5) 1.4 (0.6-3.3) 1.8 (0.8-4.2) 
Other 57 (79.2) 0.8 (0.4-1.6) 1.0 (0.5-1.8) 
M
u
sc
u
lo
sk
e
le
ta
l 
Northern European 262 (61.4) 0.010 1 1 
Caucasian American 97 (52.4) 0.7 (0.5-1.0) 0.7 (0.5-1.0) 
Southern European 24 (44.4) 0.5 (0.3-0.9) 0.5 (0.3-0.9) 
Middle Eastern / Turkish 59 (64.8) 1.2 (0.7-1.9) 1.1 (0.7-1.8) 
Chinese 20 (57.1) 0.8 (0.4-1.7) 0.8 (0.4-1.6) 
Japanese 22 (43.1) 0.5 (0.3-0.9) 0.5 (0.3-1.0) 
Indian subcontinent 36 (69.2) 1.4 (0.8-2.6) 1.3 (0.7-2.4) 
Other 46 (63.9) 1.1 (0.7-1.9) 1.0 (0.6-1.8) 
Sk
in
 
Northern European 133 (31.2) 0.354 1 1 
Caucasian American 68 (36.8) 1.3 (0.9-1.8) 1.3 (0.9-1.9) 
Southern European 18 (33.3) 1.1 (0.6-2.0) 1.1 (0.6-2.1) 
Middle Eastern / Turkish 33 (36.3) 1.3 (0.8-2.0) 1.1 (0.7-1.8) 
Chinese 11 (31.4) 1.0 (0.5-2.1) 0.9 (0.4-2.0) 
Japanese 17 (33.3) 1.1 (0.6-2.0) 1.3 (0.7-2.5) 
Indian subcontinent 21 (40.4) 1.5 (0.8-2.7) 1.3 (0.7-2.3) 
Other 33 (45.8) 1.9 (1.1-3.1) 1.7 (1.0-2.9) 
O
p
h
th
al
m
ic
 
Northern European 125 (29.3) <0.001** 1 1 
Caucasian American 42 (22.7) 0.7 (0.5-1.1) 0.7 (0.5-1.1) 
Southern European 12 (22.2) 0.7 (0.4-1.4) 0.7 (0.4-1.4) 
Middle Eastern / Turkish 20 (22.0) 0.7 (0.4-1.2) 0.6 (0.4-1.1) 
Chinese 9 (25.7) 0.8 (0.4-1.8) 0.8 (0.4-1.7) 
Japanese 1 (2.0) 0.04 (0.0-0.4) 0.05 (0.0-0.4)* 
Indian subcontinent 24 (46.2) 2.1 (1.2-3.7) 1.8 (1.0-3.3) 
Other 28 (38.9) 1.5 (0.9-2.6) 1.4 (0.8-2.4) 
O
t
o
r
h
in
o
la ry n
g
o
lo gi
c 
Northern European 306 (71.7) <0.001** 1 1 
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Caucasian American 135 (73.0) 1.1 (0.7-1.6) 1.1 (0.7-1.6) 
Southern European 32 (59.3) 0.6 (0.3-1.0) 0.6 (0.3-1.1) 
Middle Eastern / Turkish 60 (65.9) 0.8 (0.5-1.2) 0.6 (0.4-1.0) 
Chinese 19 (54.3) 0.5 (0.2-0.9) 0.4 (0.2-0.8)* 
Japanese 18 (35.3) 0.2 (0.1-0.4) 0.3 (0.2-0.5)* 
Indian subcontinent 36 (69.2) 0.9 (0.5-1.7) 0.6 (0.3-1.2) 
Other 49 (68.1) 0.8 (0.5-1.4) 0.7 (0.4-1.2) 
R
e
sp
ir
at
o
ry
 
Northern European 278 (65.1) 0.59 1 1 
Caucasian American 124 (67.0) 1.1 (0.8-1.6) 1.1 (0.8-1.6) 
Southern European 35 (64.8) 1.0 (0.5-1.8) 1.0 (0.5-1.8) 
Middle Eastern / Turkish 66 (72.5) 1.4 (0.9-2.3) 1.4 (0.9-2.4) 
Chinese 25 (71.4) 1.3 (0.6-2.9) 1.4 (0.6-2.9) 
Japanese 32 (62.8) 0.9 (0.5-1.6) 0.9 (0.5-1.6) 
Indian subcontinent 40 (76.9) 1.8 (0.9-3.5) 1.9 (0.9-3.7) 
Other 51 (70.8) 1.3 (0.8-2.2) 1.4 (0.8-2.4) 
C
ar
d
ia
c 
Northern European 68 (15.9) 0.032 1 1 
Caucasian American 39 (21.1) 1.4 (0.9-2.2) 1.4 (0.9-2.2) 
Southern European 6 (11.1) 0.7 (0.3-1.6) 0.7 (0.3-1.6) 
Middle Eastern / Turkish 6 (6.6) 0.4 (0.2-0.9) 0.4 (0.2-0.9)* 
Chinese 7 (20.0) 1.3 (0.6-3.1) 1.3 (0.6-3.1) 
Japanese 10 (19.6) 1.3 (0.6-2.7) 1.3 (0.6-2.8) 
Indian subcontinent 4 (7.7) 0.4 (0.2-1.3) 0.4 (0.2-1.3)* 
Other 15 (20.8) 1.4 (0.7-2.6) 1.4 (0.7-2.6) 
G
as
tr
o
-i
n
te
st
in
al
 
Northern European 84 (19.7) 0.203 1 1 
Caucasian American 41 (22.2) 1.2 (0.8-1.8) 1.2 (0.8-1.8) 
Southern European 8 (14.8) 0.7 (0.3-1.6) 0.7 (0.3-1.6) 
Middle Eastern / Turkish 19 (20.9) 1.1 (0.6-1.9) 1.0 (0.6-1.8) 
Chinese 9 (25.7) 1.4 (0.6-3.1) 1.4 (0.6-3.1) 
Japanese 7 (13.7) 0.6 (0.3-1.5) 0.7 (0.3-1.6) 
Indian subcontinent 15 (28.9) 1.7 (0.9-3.2) 1.6 (0.8-3.1) 
Other 22 (30.6) 1.8 (1.0-3.1) 1.8 (1.0-3.1) 
G
e
n
it
o
-u
ri
n
ar
y 
Northern European 50 (11.7) 0.018 1 1 
Caucasian American 17 (9.2) 0.8 (0.4-1.4) 0.8 (0.4-1.4) 
Southern European 2 (3.7) 0.3 (0.1-1.2) 0.3 (0.1-1.2)* 
Middle Eastern / Turkish 8 (8.8) 0.7 (0.3-1.6) 0.8 (0.4-1.7) 
Chinese 1 (2.8) 0.2 (0.0-1.7) 0.2 (0.0-1.7)* 
Japanese 10 (19.6) 1.8 (0.9-3.9) 1.7 (0.8-3.6) 
Indian subcontinent 10 (19.2) 1.8 (0.8-3.8) 2.1 (0.9-4.5) 
Other 13 (18.1) 1.7 (0.9-3.2) 1.8 (0.9-3.6) 
N
e
u
ro
lo
gi
ca
l Northern European 164 (38.4) 
0.562 1 1 
Caucasian American 82 (44.3) 1.3 (0.9-1.8) 1.3 (0.9-1.8) 
Southern European 23 (42.6) 1.2 (0.7-2.1) 1.1 (0.6-2.0) 
Middle Eastern / Turkish 31 (34.1) 0.8 (0.5-1.3) 0.9 (0.6-1.5) 
Chinese 12 (34.3) 0.8 (0.4-1.7) 0.9 (0.4-1.9) 
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Japanese 22 (43.1) 1.2 (0.7-2.2) 1.0 (0.6-1.9) 
Indian subcontinent 24 (46.2) 1.4 (0.8-2.5) 1.6 (0.9-3.0) 
Other 33 (45.8) 1.4 (0.8-2.2) 1.5 (0.9-2.5) 
*=estimated organ involvement +/- 2 fold difference from the reference (Northern European) group 
**=statistically significant, at 0. 0.0045 using a 95% significance level and the Bonferroni correction 
for testing 11 variables 
†Adjusted for age and sex 
OR = odds ratio, CI = confidence intervals, 
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Legends for illustrations: 
 
Figure 1: Distribution of patients recruited by each specialty in each ethnic 
category 
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Key Messages 
 PR3-ANCA vasculitis is the predominant type of vasculitis in Northern Europeans, Middle 
Eastern/Turkish and people from the Indian subcontinent. 
 MPO-ANCA vasculitis is the predominant subtype in Japanese and Chinese populations. 
 MPO-AAV and PR3-AAV occur with similar frequency in Caucasian Americans and Southern 
Europeans. 
 
